Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000365864
Ethics application status
Approved
Date submitted
23/03/2012
Date registered
29/03/2012
Date last updated
30/01/2015
Type of registration
Prospectively registered

Titles & IDs
Public title
Pilot Study of the V501 Product - Protocol 502: A pilot study of the ForSight Ocular System on Safety and Efficacy in Anterior Segment Eye Disease in Latvia
Scientific title
Pilot Study of the V501 Product - Protocol 502: A pilot study of the ForSight Ocular System on Safety and Efficacy in Anterior Segment Eye Disease in Latvia
Secondary ID [1] 280202 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anterior segment eye disease 286142 0
Condition category
Condition code
Eye 286335 286335 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
ForSight Ocular System (drug/device combination product) will be placed in eye. Product contains prostaglandin which elutes with varying dose over six month period. Dose is higher at beginning of use of product and gradually declines as drug elutes from product, as is typical for drug-eluting products. Maximum daily dose will not exceed levels tested in prior clinical studies. Dose will start under 100 mcg/day (maximum amount tested in prior clinical use) and will decline toward 0 mcg/day by end of study period.

The design for this study (Protocol 502) may possibly be influenced by the progress of our organisation’s corresponding, ongoing, Australian study (Protocol 501) which began in 2011 (see: http://www.ANZCTR.org.au/ACTRN12612000362897.aspx).
Intervention code [1] 284531 0
Treatment: Drugs
Intervention code [2] 284540 0
Treatment: Devices
Comparator / control treatment
No control (pilot study)
Control group
Uncontrolled

Outcomes
Primary outcome [1] 286802 0
Safety as assessed in terms of ocular and systemic AEs as determined by eye exam. AEs may include erythema, corneal scratch, lid edema.
Timepoint [1] 286802 0
Day 0,7,14,28,35, Month 2, Week 10, Months 3,4,5,6,7.
Secondary outcome [1] 296685 0
Efficacy as measured by tonometry.
Timepoint [1] 296685 0
Day 0,7,14,28,35, Month 2, Week 10, Months 3,4,5,6,7.
Secondary outcome [2] 296686 0
Mechanical device design acceptability as measured by patient comfort questionnaires designed by ForSight.
Timepoint [2] 296686 0
Day 0,7,14,28,35, Month 2, Week 10, Months 3,4,5,6,7.

Eligibility
Key inclusion criteria
Subjects who are diagnosed with certain types of anterior segment eye disease in at least one eye.

Subjects with mean deviation on Visual Field of -12 dB or less.

Subjects with no visual field loss within 10 degrees of fixation.

Cup-to-disc ratio of 0.8 or less.

Subjects whom the Investigator deems can be safely washed out of their medications as described in this study.

Females of child-bearing age who are not breast-feeding and who are using an acceptable form of birth control/contraception and plan to continue doing so throughout the study duration.

Subjects currently receiving treatment with a prostaglandin

Subjects who are able to understand the requirements of the study and willing to follow study instructions, to provide written informed consent to participate, and who agree to comply with all study requirements, including the required study follow-up visits.
Minimum age
21 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Certain prior eye surgeries including SLT or filtering surgery within the last three years, patients who have had any ophthalmic surgery within the last three months, or who have had corneal or refractive surgery.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/04/2012
Actual
2/04/2012
Date of last participant enrolment
Anticipated
Actual
19/07/2012
Date of last data collection
Anticipated
Actual
Sample size
Target
30
Accrual to date
Final
Recruitment outside Australia
Country [1] 4217 0
Latvia
State/province [1] 4217 0

Funding & Sponsors
Funding source category [1] 284952 0
Commercial sector/Industry
Name [1] 284952 0
ForSight VISION5, Inc
Country [1] 284952 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
ForSight VISION5, Inc
Address
191 Jefferson Dr.
Menlo Park, CA 94025
Country
United States of America
Secondary sponsor category [1] 283824 0
None
Name [1] 283824 0
Address [1] 283824 0
Country [1] 283824 0

Ethics approval
Ethics application status
Approved

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 33967 0
A/Prof Guna Laganovska
Address 33967 0
P. Stradins University Hospital
Pilsonu Str.
Riga, Latvia
Country 33967 0
Latvia
Phone 33967 0
Contact Sponsor: +1-650-325-2050
Fax 33967 0
Email 33967 0
Contact Sponsor: latvia@forsightv5.com
Contact person for public queries
Name 17214 0
Anne Rubin
Address 17214 0
ForSight VISION5, Inc
191 Jefferson Dr.
Menlo Park, CA 94025
Country 17214 0
United States of America
Phone 17214 0
+1-650-325-2050
Fax 17214 0
Email 17214 0
latvia@forsightv5.com
Contact person for scientific queries
Name 8142 0
Anne Rubin
Address 8142 0
ForSight VISION5, Inc
191 Jefferson Dr.
Menlo Park, CA 94025
Country 8142 0
United States of America
Phone 8142 0
+1-650-325-2050
Fax 8142 0
Email 8142 0
latvia@forsightv5.com

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.